CD274 and neoplasm: Numerous studies have identified biomarkers predicting response of anti-PD-1 therapy, and found that tumor mutational load, dense CD8+ T-cell infiltrates, and PD-L1 expression may be biomarkers to help select responders to anti-PD-1 Ab (12–15).